Abstract：
The study evaluated how ingestion of nicotinamide mononucleotide (NMN) for 12 weeks by older adults affected blood nicotinamide adenine dinucleotide (NAD +) levels and physical function, particularly walking function. Information concerning sleep, and stress was also collected as secondary endpoints. In this randomized, placebo-controlled, double-blind, parallel-group comparison study, 60 participants were randomly allocated into a placebo group or NMN group. Members of the NMN group consumed 250 mg/day NMN for 12 weeks. Motor function tests, blood NAD metabolite analysis, and questionnaires were conducted at the start of the study and 4 and 12 weeks after intake. This trial was registered at umin.ac.jp/ctr as UMIN000047871 on June 22nd, 2022.At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test. At secondary outcomes, after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites. A significant negative correlation was observed between the change in the 4-m walking time and the change in blood NAD + , N1-methyl-2-pridone-5-carboxamide (2-PY), and N1-methyl-4-pridone-3-carboxamide (4-PY) at 12 weeks. The NMN group had improved sleep quality at 12 weeks relative to the placebo group as evidenced by lower scores for \"Daytime dysfunction\" and \"Global PSQI\" on the Pittsburgh Sleep Questionnaire. No adverse effects related to test substance consumption were observed. Together, these results indicate that NMN intake could increase blood NAD + levels, maintain walking speed, and improve sleep quality in older adults. Interventions involving NMN aimed at maintaining walking speed could contribute to extended healthy life expectancy.
摘要：
该研究评估了老年人摄入烟酰胺单核苷酸（NMN）12周如何影响血液中烟酰胺腺嘌呤二核苷酸（NAD）水平和身体功能，特别是行走功能。关于睡眠的信息，并收集压力作为次要终点。在这个随机的，安慰剂对照,双盲,平行组比较研究,60名参与者被随机分配到安慰剂组或NMN组。NMN组的成员消耗250mg/天的NMN,持续12周。运动功能测试,血液NAD代谢物分析，在研究开始时以及摄入后4周和12周进行问卷调查。这项审判在umin注册。AC.jp/ctr作为UMIN000047871在6月22日，2022年。在主要结果，在4周和12周，NMN组和安慰剂组在步进试验中没有显著差异.在次要结果中，NMN摄入12周后，与安慰剂组相比,NMN组的4-m步行时间显著缩短,并且NAD+及其代谢物的血液水平显著升高.4米步行时间的变化与血液NAD+的变化呈显著负相关,N1-甲基-2-普利酮-5-甲酰胺（2-PY），和N1-甲基-4-普利酮-3-甲酰胺（4-PY）在12周。与安慰剂组相比，NMN组在12周时的睡眠质量有所改善，匹兹堡睡眠问卷上的“日间功能障碍”和“全球PSQI”得分较低。没有观察到与测试物质消耗相关的不良反应。一起,这些结果表明，NMN的摄入可以增加血液NAD+水平，保持步行速度，改善老年人的睡眠质量。涉及NMN的旨在保持步行速度的干预措施可能有助于延长健康预期寿命。
